Boehringer Signs AI Drug Discovery Deal With Owkin

Boehringer Ingelheim has partnered with artificial intelligence firm Owkin to accelerate drug discovery efforts focused on cancer and immunology. The collaboration marks another major industry move as pharmaceutical companies increasingly integrate machine learning into early-stage research.